BioHack London delivered it quickly with full documentation
Disclosures: Robert Wong: Theratechnologies: Grant/Research Support, Durect: Grant/Research Support, Gilead Sciences: Grant/Research Support, Exact Sciences: Grant/Research Support, Theratechnologies: Grant/Research Support, Durect Corporation: Grant/Research Support, Leland Yee: Gilead Sciences: Employee, Yunhao Liu: Gilead Sciences: Employee, Laura Telep: Gilead Sciences, LLC: Employee, Gilead Sciences, LLC: Stock - publicly traded company, Shahed Iqbal: Gilead Sciences, Inc.: Stockholder, Gilead Sciences, Inc.: Stock - publicly traded company, Gilead Sciences, Inc.: Employee, Sarjita Naik: Gilead Sciences: Employee, Gilead Sciences: Stock privately held company, Betty Chiang: Nothing to Disclose, Amanda Singer: Gilead Sciences: Employee, Gilead Sciences: Stock - publicly traded company, Anand Chokkalingam: Nothing to Disclose, Catherine Frenette: Nothing to Disclose 907 DISPARITIES IN PRIMARY BILIARY CHOLANGITIS: A RETROSPECTIVE STUDY USING REAL-WORLD DATA FROM A SINGLE HEPATOLOGY CLINIC IN THE GREATER LOS ANGELES AREA Sabrina Alff 1 Orlinda Ventura 1 Trinity Love Foster-Malave 1 Michel Mendler 1 Edward Mena 2 , 1 California Liver Research Institute, 2 California Liver Reasearch Institiute Background: Primary Biliary Cholangitis (PBC) is an autoimmune disease that leads to cirrhosis
For personalized recommendations, consider taking our AI quiz to determine the best supplement for your needs.
Clean, highly absorbable, and expertly formulated helping you look and feel your best from the inside out.* With Cymbiotika, youre not just taking a supplementyoure joining a community of people who value wellness, science, and the power of transparency
